The Maxwell Finland Lecture 2025: Antimicrobial Resistance At The Bedside: Translating Science Into Patient Outcomes.
Where this comes from
- Record sourced from PubMed, PMID 42186241.
- Also identified by DOI 10.1093/infdis/jiag273.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Antimicrobial resistance (AMR) is one of the most pressing public health threats of the 21st century. The development of resistance to antimicrobial agents is multifactorial. However, a major driver of AMR is the remarkable capacity of microorganisms to rapidly evolve, continually challenging the practice of infectious diseases and undermining the effectiveness of miracle drugs we call antibiotics. Dr. Maxwell Finland was a pioneer in this field, uniquely positioned to witness-and help shape-the transition from an era without antimicrobials to one transformed by life-saving therapies that revolutionized medicine. As AMR continues to rise and antibiotics cease to be effective, Dr. Finland's legacy is more relevant than ever.